Ingenuity Blog
Our Latest News and Biomanufacturing Thoughts
Filter by:
Loading...
Cytovance Biologics launches in-house formulation development, expanding end-to-end CDMO services for biotech and pharma customers.
Blog Post, Thought Leadership
While biopharma at large faces unprecedented pressure to innovate quickly and stay competitive, small biotech organizations are particularly impacted by...
Partnership
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and...
Partnership
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and...
Partnership
New year, new programs! Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available...
This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide...
Partnership
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and...
Blog Post, Thought Leadership
The Clinical Translation from Bench to BedsideBringing new and innovative therapeutics to patients is a fundamental purpose of translational science....
Blog Post, Thought Leadership
Like most industries, the ever-evolving biopharmaceutical landscape often experiences its ebbs and flows, with emerging biotechnology companies feeling the direst...
Partnership
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and...
This partnership provides the industry with an integrated solution for customers seeking to outsource cell line development through to cGMP...
Blog Post, Thought Leadership
Discover the role of Artificial Intelligence in revolutionizing biologics manufacturing and learn how Cytovance and partners at the University of...
End of content
No more pages to load
